Lung Cancer Europe shared a post on LinkedIn:
“It’s really encouraging to see so many lung cancer papers across ASCO’s JCO Journals Top Articles of 2025.
Lung cancer appears not just in new treatments, but in work on EGFR and ROS1 targeted therapies, ctDNA monitoring, stage III disease, and screening systems.
Papers on neoadjuvant osimertinib and taletrectinib underline how critical early and consistent biomarker testing is. Research on ctDNA strengthens the case for smarter follow-up and earlier detection of change.
Taken together, this evidence shows the importance of equitable access to testing, treatment, and monitoring, which is at the heart of Lung Cancer Europe’s policy work.”
More posts featuring Lung Cancer Europe.